Only after adjusting for total fat , participants on rosiglitazone had 23 cm less visceral adipose tissue area ( P = 0.01 ) and an 0.08-unit higher liver : spleen attenuation ratio ( i.e. less hepatic fat ; P = 0.02 ) than those on the placebo .